Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Atomic Force Microscopy Reveals Cell Stiffness as Potential Biomarker

By LabMedica International staff writers
Posted on 24 Oct 2012
New findings reveal that cell stiffness could be potential evidence for clinicians as they look for and treat cancerous cells before they are able to metastasize. More...
The research demonstrated that highly metastatic ovarian cancer cells are several times softer than less metastatic ovarian cancer cells.

Georgia Institute of Technology (Georgia Tech; Atlanta, USA) assistant professor Dr. Todd Sulchek and PhD student Wenwei Xu used technology called atomic force microscopy (AFM) to examine the mechanical characteristics of various ovarian cell lines. A soft mechanical probe “tapped” healthy, malignant, and metastatic ovarian cells to measure their stiffness.

The study‘s findings were published October 4, 2012, in the journal PLoS One. “In order to spread, metastatic cells must force themselves into the bloodstream. As a result, they must be highly deformable and softer,” said Dr. Sulchek, a faculty member in the George W. Woodruff School of Mechanical Engineering. “Our results indicate that cell stiffness may be a useful biomarker to evaluate the relative metastatic potential of ovarian and perhaps other types of cancer cells.”

Just as earlier research on other types of epithelial cancers have indicated, Dr. Sulchek also discovered that cancerous ovarian cells are generally softer and display lower intrinsic variability in cell stiffness than nonmalignant cells. Dr. Sulchek’s lab collaborated with Prof. John McDonald, who is also director of Georgia Tech’s newly established Integrated Cancer Research Center. “This is a good example of the kinds of discoveries that only come about by integrating skills and knowledge from traditionally diverse fields such as molecular biology and bioengineering,” said Prof. McDonald. “Although there are a number of developing methodologies to identify circulating cancer cells in the blood and other body fluids, this technology offers the added potential to rapidly determine if these cells are highly metastatic or relatively benign.”

Dr. Sulchek and Prof. McDonald hope that, when further modified, this technology could offer a great benefit to clinicians in the creation of optimal chemotherapies, for ovarian cancer patients and patients of other types of cancer.

Related Links:

Georgia Institute of Technology



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.